Active, Not Recruiting
A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France - CA209-7HU
Atualizado: 17 março, 2022 | ClinicalTrials.gov
Gênero(s)
Faixa etária
Active, Not Recruiting
For more information regarding Bristol-Myers Squibb Clinical Trial participation,please visit www.BMSStudyConnect.com. Inclusion Criteria: - Participants with a primary diagnosis of melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection and have no evidence of disease - Decision to treat with adjuvant nivolumab therapy has already been taken - Participants who provide oral informed consent to participate in the study Exclusion Criteria: - Any participant with a current diagnosis of persisting advanced melanoma - Participants with a current primary diagnosis of a cancer other than advanced melanoma, ie, a cancer other than melanoma that requires systemic or other treatment or has not been treated curatively (as per discretion of the investigator) - Any participants currently enrolled in an interventional clinical trial for his/her melanoma treatment (note: patients who have completed their participation in an interventional trial or who are no longer receiving the study drug and are only followed up for OS/RFS can be enrolled. In case of a blinded study, the treatment arm needs to be known). - Pregnant women - Person under guardianship Other protocol defined inclusion/exclusion criteria apply
É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas
